Log in

NASDAQ:ARGXargenx Stock Price, Forecast & News

$228.72
+0.86 (+0.38 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$228.01
Now: $228.72
$232.90
50-Day Range
$155.96
MA: $208.21
$232.72
52-Week Range
$103.75
Now: $228.72
$242.37
Volume138,252 shs
Average Volume150,763 shs
Market Capitalization$10.75 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.22
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Read More
argenx logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.19 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARGX
CUSIPN/A
Phone329-310-3400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$78.17 million
Book Value$30.88 per share

Profitability

Miscellaneous

Employees103
Market Cap$10.75 billion
Next Earnings DateN/A
OptionableOptionable

Receive ARGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter.

argenx (NASDAQ:ARGX) Frequently Asked Questions

How has argenx's stock been impacted by COVID-19 (Coronavirus)?

argenx's stock was trading at $133.81 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARGX stock has increased by 70.9% and is now trading at $228.72. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of argenx?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 2 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for argenx.

How were argenx's earnings last quarter?

argenx SE - (NASDAQ:ARGX) issued its earnings results on Thursday, May, 14th. The company reported ($1.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.72) by $0.15. The firm earned $21.15 million during the quarter, compared to analyst estimates of $18.08 million. View argenx's earnings history.

What price target have analysts set for ARGX?

16 analysts have issued twelve-month target prices for argenx's stock. Their forecasts range from $125.00 to $258.00. On average, they expect argenx's share price to reach $220.40 in the next twelve months. This suggests that the stock has a possible downside of 3.6%. View analysts' price targets for argenx.

Has argenx been receiving favorable news coverage?

Media headlines about ARGX stock have trended negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. argenx earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about argenx.

Who are some of argenx's key competitors?

What other stocks do shareholders of argenx own?

Who are argenx's key executives?

argenx's management team includes the following people:
  • Mr. Tim Van Hauwermeiren, CEO & Exec. Director (Age 47)
  • Mr. Eric Castaldi, Chief Financial Officer (Age 55)
  • Prof. Hans de Haard, Chief Scientific Officer (Age 59)
  • Mr. Dirk Marcel Leon Beeusaert, Gen. Counsel (Age 55)
  • Dr. Torsten Dreier, Chief Devel. Officer (Age 55)

When did argenx IPO?

(ARGX) raised $65 million in an initial public offering (IPO) on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is argenx's stock symbol?

argenx trades on the NASDAQ under the ticker symbol "ARGX."

How do I buy shares of argenx?

Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is argenx's stock price today?

One share of ARGX stock can currently be purchased for approximately $228.72.

How big of a company is argenx?

argenx has a market capitalization of $10.75 billion and generates $78.17 million in revenue each year. The company earns $-182,520,000.00 in net income (profit) each year or ($4.73) on an earnings per share basis. argenx employs 103 workers across the globe.

What is argenx's official website?

The official website for argenx is www.argenx.com.

How can I contact argenx?

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at 329-310-3400 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.